Audit preparedness is essential for every clinical research site. By operationalizing compliance in your daily procedures, you can effectively mitigate risk and ensure smooth inspections. Start by thoroughly educating key personnel on current regulations and any changes, and involve them in risk identification and mitigation strategies. Foster a culture of shared responsibility through ongoing training and open communication. Keep detailed documentation of the reasoning behind your procedures and policies, and store all standard operating procedures (SOPs) in a central, easily accessible location. Finally, implement a robust system for managing data and documents to ensure that all necessary information is readily available for internal and external monitors, as well as regulatory agencies.
Clinical trial audits—whether conducted by the FDA, Health Canada, or another agency—play a critical role in ensuring compliance, data integrity, and participant safety. With the right preparation, your site can confidently navigate these audits and minimize risk. Here’s a step-by-step guide to getting your clinical site audit-ready:
Build Compliance into Daily Operations
Audit readiness starts long before you get a notification from regulators. To mitigate risk and ensure ongoing compliance:
- Educate Key Personnel: Regularly train your team on current regulations and any changes. Make education an ongoing process and involve operational staff in identifying and mitigating risks.
- Document Decision-Making: Keep records of the factors considered when developing procedures and policies.
- Centralize Documentation: Store all SOPs in an accessible, central location for easy reference and sharing.
- Data Management: Ensure all data and documents are stored securely and can be accessed by internal/external monitors and regulatory agencies as needed.
Data Integrity and Participant Safety
- Timely Data Entry: Enter data promptly to maintain accuracy and reliability.
- Electronic Signature Compliance: Adhere to 21 CFR Part 11. Consider mobile signatures to facilitate compliance.
- Participant Welfare: Prioritize participant safety and welfare at every stage. Maintain robust training, secure investigational drugs, and keep thorough records.
- Maintain Records: Ensure records are accurate, complete, and readily available for review.
Understand Regulatory Inspections
Inspections assess whether your site operates in a state of control and produces reliable, high-quality data. Regulatory agencies conduct various types of inspections:
- For-Cause Inspections: Triggered by specific concerns or complaints.
- Pre-Approval/Pre-License Inspections: Part of the review process for new products.
- Routine Surveillance: Ongoing monitoring of compliance.
Be Inspection Ready
Prior to an inspection, it is crucial to thoroughly review your records for any quality issues and to have a clear understanding of trends in protocol deviations, along with the mitigation actions that have been implemented. Ensure that access to data is appropriately controlled to prevent inadvertent unblinding, and that the Principal Investigator’s obligations are clearly delineated through a well-maintained delegation of authority log. Verify that all staff have the necessary qualifications and training on the study protocols, and confirm compliance with eligibility requirements, including proper documentation of inclusion and exclusion criteria. Additionally, make sure that all protocol amendments and approvals are in place before study initiation. Open communication with your team about any known issues and how to address them prior to inspection is essential for demonstrating preparedness and maintaining compliance.
- Accurate Records: Maintain records that are attributable, legible, timely, and complete, whether paper or electronic.
- Regular Communication: Stay in touch with study sponsors and monitors.
- Role Assignment: Pre-assign roles for inspections (primary host, scribe, etc.) and train staff—including reception—on procedures if an inspector arrives.
- Protect Participants: Follow procedures to safeguard participant rights, safety, and welfare. Address and document any deficiencies.
Key Audit Preparedness Steps
- Review Records: Regularly audit your own records for quality issues and protocol deviations.
- Delegation Logs: Maintain up-to-date delegation of authority logs.
- Staff Qualifications: Confirm training and qualifications for all staff.
- Protocol Compliance: Ensure adherence to inclusion/exclusion criteria and protocol amendments.
- Team Communication: Discuss any known issues and ensure everyone is prepared to address them during an inspection.
Know What Inspectors May Request
Be prepared to provide:
- Organizational charts
- Training records
- Protocol amendments/deviations
- IRB communications
- Informed consent forms
- Screening logs
- Investigational product records (labeling, storage, chain of custody, etc.)
- Monitoring and safety reports
- Regulatory documents and investigator site files
- Source documents (medical records, lab results, participant diaries, etc.)
During the Audit: Best Practices
During the audit, it is important to first confirm the focus of the inspection so your team can be responsive to the auditor’s priorities. Carefully document all questions asked and responses provided, and maintain a detailed log of any documents requested by the FDA. Throughout the process, keep your trial site team updated on the progress and status of FDA discussions to ensure everyone is aligned. If the audit is conducted via video conference, be prepared to access and share electronic data and documents as needed. Listen attentively to the inspector’s inquiries, seek clarification when necessary, and respond with accurate facts and data. If you are uncertain about a question, it is appropriate to defer and follow up with the correct information. Strive to address any potential misunderstandings promptly to ensure clear and transparent communication throughout the inspection.
- Host, Scribe & Photographer: Decide the roles of each person for the inspection. Train your receptionist as to who to contact if FDA appears onsite, etc. The designated host communicates with the inspector; a scribe documents all interactions and requests; a photographer captures everything the inspector is examining.
- Communication plan: who will communicate, when, how (email, phone, etc.), what will be communicated, who will be supporting the inspection.
- Find a place(s) on site where the FDA/DEA inspector can inspect your documents/records
- Consider your document request process: when the inspector requests a record, how will you retrieve it
- Consider if printer, copier, telecommunications, network and projection equipment are needed for the FDA inspector to review records after the inspector requests them
- Know your systems and processes (electronic records, signatures, data security)
- Inspector Credentials: Inspectors will present official credentials and a Notice of Inspection. (FDA Form 482). See https://www.fda.gov/industry/fda-basics-industry/what-should-i-expect-during-inspection
- Clarify Scope: Confirm the scope of the inspection and log all questions and responses. Log all documents requested by the inspector.
- Real-Time Communication: Keep your team informed of audit progress. Communicate with trial site team as to progress and status of FDA discussions during the inspection.
- Be Responsive: Answer questions with facts and data, and clarify as needed.
After the Inspection
After the inspection, it is essential to communicate internally with your team to review the findings and discuss next steps. If the FDA issues a Form 483, Inspectional Observations, you are required to provide a written response within 15 business days, addressing each observation and outlining any corrective actions taken or planned. Keep in mind that Form 483 letters, while not always published, can be requested by the public through the FDA’s website under the Freedom of Information Act. Use this opportunity to carefully review the inspection outcomes with your team, identify any process gaps or deficiencies, and implement improvements to strengthen compliance and prevent future issues. For more information on responding to FDA 483 observations, visit FDA Inspection Observations.
- FDA Form 483: If issued, this details any objectionable conditions found. Respond within 15 business days.
- Public Disclosure: Form 483 letters can be published or requested via the Freedom of Information Act.
- Continuous Improvement: Review findings with your team and implement process improvements as needed.
- Keep in mind: violations can be issued for events that happened long ago.
Conclusion
Audit preparedness isn’t a one-time event—it’s a culture of compliance, documentation, and continual improvement. By building these principles into your daily operations, you’ll be ready for any inspection and, most importantly, you’ll ensure the safety and rights of your participants and the integrity of your data.
[View source.]
